Department of Laboratory Medicine, Chonnam National University Medical School and Chonnam National University Hospital, Gwangju, Republic of Korea.
Department of Laboratory Medicine, Chonnam National University Medical School and Chonnam National University Hospital, Gwangju, Republic of Korea
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.00740-20.
The abilities of the new Vitek 2 AST-YS08 (YS08) and Sensititre YeastOne (SYO) systems to detect the resistances of isolates to azoles and echinocandins were evaluated. In total, 292 isolates, including 28 (6 Erg11 and 2 Fks mutants), 57 (26 Erg11 mutants), 24 (10 Erg11 and 1 Fks mutants), and 183 (39 Pdr1 and 13 Fks mutants) isolates, were tested. The categorical agreements (CAs) between the Clinical and Laboratory Standards Institute (CLSI) method and YS08 fluconazole MICs obtained using clinical breakpoints were 92.4% (), 96.5% (), and 87.0% (), and the CAs between the CLSI and SYO MICs were 92.3% (), 77.2% (), 100% (), and 98.9% (). For , the CAs with the CLSI micafungin MICs were 92.4% and 55.5% for the YS08 micafungin and caspofungin MICs, respectively; they were 100%, 95.6%, and 98.9% for the SYO micafungin, caspofungin, and anidulafungin MICs, respectively. YS08 does not provide fluconazole data for ; the CA with the CLSI fluconazole MIC was 97.8% for the YS08 voriconazole MIC, using an epidemiological cutoff value (ECV) of 0.5 μg/ml. Increased CAs with the CLSI MIC were observed for the YS08 MIC using CLSI ECVs (for fluconazole and , 100%; for micafungin and , 98.9%) and for the SYO MIC using method-specific ECVs (for fluconazole and , 91.2%; for caspofungin and , 98.9%). Therefore, the YS08 and SYO systems may have different abilities to detect mechanisms of azole and echinocandin resistance in four species; the use of method-specific ECVs may improve the performance of both systems.
评估了新的 Vitek 2 AST-YS08（YS08）和 Sensititre YeastOne（SYO）系统检测唑类和棘白菌素类耐药性的能力。共有 292 株分离株进行了测试，包括 28 株（6 株 Erg11 和 2 株 Fks 突变株）、57 株（26 株 Erg11 突变株）、24 株（10 株 Erg11 和 1 株 Fks 突变株）和 183 株（39 株 Pdr1 和 13 株 Fks 突变株）。采用临床折点获得的氟康唑 MICs 时，CLSI 方法与 YS08 氟康唑 MICs 的分类一致性（CA）分别为 92.4%（）、96.5%（）和 87.0%（），CLSI 与 SYO MICs 的 CA 分别为 92.3%（）、77.2%（）、100%（）和 98.9%（）。对于，与 CLSI 米卡芬净 MICs 的 CA 分别为 YS08 米卡芬净和卡泊芬净 MICs 的 92.4%和 55.5%；与 SYO 米卡芬净、卡泊芬净和安尼芬净 MICs 的 CA 分别为 100%、95.6%和 98.9%。YS08 不提供氟康唑数据，采用流行病学折点（ECV）为 0.5μg/ml 时，CLSI 氟康唑 MIC 的 CA 为 97.8%，为 YS08 伏立康唑 MIC。使用 CLSI ECV（氟康唑和，100%；米卡芬净和，98.9%）和 SYO MIC 使用方法特异性 ECV（氟康唑和，91.2%；卡泊芬净和，98.9%）时，YS08 MIC 的 CA 有所增加。因此，YS08 和 SYO 系统可能具有不同的能力来检测四种酵母属中唑类和棘白菌素类耐药机制；使用方法特异性 ECV 可能会提高两个系统的性能。
